1 Introduction 7

• 1.1 Industry Definition and Research Scope 7
  • 1.1.1 Industry Definition 7
  • 1.1.2 Research Scope 8
• 1.2 Research Methodology 11
  • 1.2.1 Overview of Market Research Methodology 11
  • 1.2.2 Market Assumption 12
  • 1.2.3 Secondary Data 12
  • 1.2.4 Primary Data 12
  • 1.2.5 Data Filtration and Model Design 14
  • 1.2.6 Market Size/Share Estimation 15
  • 1.2.7 Research Limitations 16
• 1.3 Executive Summary 17

2 Market Overview and Dynamics 20

• 2.1 Market Size and Forecast 20
  • 2.1.1 Impact of COVID-19 on the Market 21
• 2.2 Major Growth Drivers 23
• 2.3 Market Restraints and Challenges 27
• 2.4 Emerging Opportunities and Market Trends 30
• 2.5 Porter’s Fiver Forces Analysis 34

3 Segmentation of Asia Pacific Market by Drug Class 38

• 3.1 Market Overview by Drug Class 38
• 3.2 Cephalosporin 40
• 3.3 Penicillin 42
• 3.4 Macrolides 43
• 3.5 Tetracycline 44
• 3.6 Quinolones 45
• 3.7 Sulfonamides 46
• 3.8 Aminoglycosides 47
• 3.9 Other Drug Classes 48

4 Segmentation of Asia Pacific Market by Action Mechanism 49

• 4.1 Market Overview by Action Mechanism 49
• 4.2 Cell Wall Synthesis Inhibitors 51
• 4.3 Mycolic Acid Inhibitors 52
• 4.4 RNA Synthesis Inhibitors 53
• 4.5 DNA Synthesis Inhibitors 54
• 4.6 Protein Synthesis Inhibitors 55
• 4.7 Other Mechanisms 56

5 Segmentation of Asia Pacific Market by Drug Origin 57

• 5.1 Market Overview by Drug Origin 57
• 5.2 Natural Antibiotics 59
• 5.3 Semi-synthetic Antibiotics 60
• 5.4 Synthetic Antibiotics 61

6 Segmentation of Asia Pacific Market by Activity Spectrum 62

• 6.1 Market Overview by Activity Spectrum 62
• 6.2 Broad-spectrum Antibiotics 64
• 6.3 Narrow-spectrum Antibiotics 65

7 Segmentation of Asia Pacific Market by Application 66

• 7.1 Market Overview by Application 66
• 7.2 Urinary Tract Infections (UTIS) 68
• 7.3 Dental Infections 69
  • 7.3.1 Monotherapies for Dental Infections 70
  • 7.3.2 Combined Therapies for Dental Infections 71
• 7.4 Respiratory Tract Infections (RTIS) 72
  • 7.4.1 Upper Respiratory Tract Infections (URTI) 73
  • 7.4.2 Lower Respiratory Tract Infections (LRTIs) 74
• 7.5 Other Applications 75

8 Segmentation of Asia Pacific Market by Drug Type 76

• 8.1 Market Overview by Drug Type 76
• 8.2 Brand Antibiotics 78
• 8.3 Generic Antibiotics 79

9 Asia-Pacific Market 2019-2030 by Country 80

• 9.1 Overview of Asia-Pacific Market 80
• 9.2 Japan 83
• 9.3 China 86
• 9.4 Australia 88
• 9.5 India 90
• 9.6 South Korea 92
• 9.7 Rest of APAC Region 94

10 Competitive Landscape 96

• 10.1 Overview of Key Vendors 96
• 10.2 New Product Launch, Partnership, Investment, and M&A 99
• 10.3 Company Profiles 100

Abbott Laboratories 100

Astellas Pharma 102

AstraZeneca Plc 103

Bayer AG 104

Bristol Myers Squibb Company 105

Cipla Inc. 106

Dr. Reddy’s Laboratories Ltd. 107

Eli Lilly and Company 108

F. Hoffmann-La Roche Ltd. 109

Gilead Sciences, Inc. 110

GlaxoSmithKline plc. 111

Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals) 112

Mayne Pharma Group Ltd. 113

MELINTA THERAPEUTICS, INC. 114

Merck KGaA 115

Novartis AG 116

Pfizer Inc. 117

Sanofi 118

Sun Pharmaceutical Industries Ltd. 119

11 Investing in Asia Pacific Market: Risk Assessment and Management 120

• 11.1 Risk Evaluation of Asia Pacific Market 120
• 11.2 Critical Success Factors (CSFs) 123

Related Reports and Products 126

Asia Pacific oral antibiotics market will grow by 4.6% annually with a total addressable market cap of $103.3 billion over 2020-2030 owing to the rising infection complications associated with COVID-19 epidemic, development of innovative antibiotics, and growing healthcare expenditure.
Highlighted with 35 tables and 62 figures, this 126-page report “Asia Pacific Oral Antibiotics Market 2020-2030 by Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Application, Drug Type, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific oral antibiotics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific oral antibiotics market in every aspect of the classification from perspectives of Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Application, Drug Type, and Country.

Based on Drug Class, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
Cephalosporin
• Cefuroxime Axetil
• Cephalexin
• Cefixime
• Cefpodoxime
• Other Cephalosporin
Penicillin
Macrolides
Tetracycline
Quinolones
Sulfonamides
Aminoglycosides
Other Drug Classes

Based on Action Mechanism, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Cell Wall Synthesis Inhibitors
• Mycolic Acid Inhibitors
• RNA Synthesis Inhibitors
• DNA Synthesis Inhibitors
• Protein Synthesis Inhibitors
• Other Mechanisms

Based on Drug Origin, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Natural Antibiotics
• Semi-synthetic Antibiotics
• Synthetic Antibiotics

Based on Activity Spectrum, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Broad-spectrum Antibiotics
• Narrow-spectrum Antibiotics

Based on Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
Urinary Tract Infections (UTIS)
• Upper Respiratory Tract Infections (URTI)
• Lower Respiratory Tract Infections (LRTIs)
Dental Infections
• Monotherapies
• Combined Therapies
Respiratory Tract Infections (RTIS)
Other Applications

Based on Drug Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Brand Antibiotics
• Generic Antibiotics

Geographically, the following national/local markets are fully investigated:
• Japan
• China
• South Korea
• Australia
• India
• Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)
For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Drug Class, Drug Origin, and Application over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in Asia Pacific oral antibiotics market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
Abbott Laboratories
Astellas Pharma
AstraZeneca Plc
Bayer AG
Bristol Myers Squibb Company
Cipla Inc.
Dr. Reddy’s Laboratories Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
GlaxoSmithKline plc.
Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)
Mayne Pharma Group Ltd.
MELINTA THERAPEUTICS, INC.
Merck KGaA
Novartis AG
Pfizer Inc.
Sanofi
Sun Pharmaceutical Industries Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)